517 related articles for article (PubMed ID: 23608605)
1. Senile systemic amyloidosis: clinical features at presentation and outcome.
Pinney JH; Whelan CJ; Petrie A; Dungu J; Banypersad SM; Sattianayagam P; Wechalekar A; Gibbs SD; Venner CP; Wassef N; McCarthy CA; Gilbertson JA; Rowczenio D; Hawkins PN; Gillmore JD; Lachmann HJ
J Am Heart Assoc; 2013 Apr; 2(2):e000098. PubMed ID: 23608605
[TBL] [Abstract][Full Text] [Related]
2. Left ventricular structure and function in transthyretin-related versus light-chain cardiac amyloidosis.
Quarta CC; Solomon SD; Uraizee I; Kruger J; Longhi S; Ferlito M; Gagliardi C; Milandri A; Rapezzi C; Falk RH
Circulation; 2014 May; 129(18):1840-9. PubMed ID: 24563469
[TBL] [Abstract][Full Text] [Related]
3. Identification of prognostic markers in transthyretin and AL cardiac amyloidosis.
Damy T; Jaccard A; Guellich A; Lavergne D; Galat A; Deux JF; Hittinger L; Dupuis J; Frenkel V; Rigaud C; Plante-Bordeneuve V; Bodez D; Mohty D
Amyloid; 2016 Sep; 23(3):194-202. PubMed ID: 27647161
[TBL] [Abstract][Full Text] [Related]
4. Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types.
Rapezzi C; Merlini G; Quarta CC; Riva L; Longhi S; Leone O; Salvi F; Ciliberti P; Pastorelli F; Biagini E; Coccolo F; Cooke RM; Bacchi-Reggiani L; Sangiorgi D; Ferlini A; Cavo M; Zamagni E; Fonte ML; Palladini G; Salinaro F; Musca F; Obici L; Branzi A; Perlini S
Circulation; 2009 Sep; 120(13):1203-12. PubMed ID: 19752327
[TBL] [Abstract][Full Text] [Related]
5. Osteopontin: a novel predictor of survival in patients with systemic light-chain amyloidosis.
Kristen AV; Rosenberg M; Lindenmaier D; Merkle C; Steen H; Andre F; Schönland SO; Schnabel PA; Schuster T; Röcken C; Giannitsis E; Katus HA; Frey N
Amyloid; 2014 Sep; 21(3):202-10. PubMed ID: 25007036
[TBL] [Abstract][Full Text] [Related]
6. Matrix metalloproteinases and their tissue inhibitors in cardiac amyloidosis: relationship to structural, functional myocardial changes and to light chain amyloid deposition.
Biolo A; Ramamurthy S; Connors LH; O'Hara CJ; Meier-Ewert HK; Soo Hoo PT; Sawyer DB; Seldin DC; Sam F
Circ Heart Fail; 2008 Nov; 1(4):249-57. PubMed ID: 19808299
[TBL] [Abstract][Full Text] [Related]
7. Echocardiographic and biohumoral characteristics in patients with AL and TTR amyloidosis at diagnosis.
Cappelli F; Baldasseroni S; Bergesio F; Perlini S; Salinaro F; Padeletti L; Attanà P; Paoletti Perini A; Moggi Pignone A; Grifoni E; Fabbri A; Marchionni N; Gensini GF; Perfetto F
Clin Cardiol; 2015 Feb; 38(2):69-75. PubMed ID: 25645201
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of right ventricular systolic function in cardiac amyloidosis.
Bodez D; Ternacle J; Guellich A; Galat A; Lim P; Radu C; Guendouz S; Bergoend E; Couetil JP; Hittinger L; Dubois-Randé JL; Plante-Bordeneuve V; Deux JF; Mohty D; Damy T
Amyloid; 2016 Sep; 23(3):158-167. PubMed ID: 27348696
[TBL] [Abstract][Full Text] [Related]
9. Prognosis of Light Chain Amyloidosis With Preserved LVEF: Added Value of 2D Speckle-Tracking Echocardiography to the Current Prognostic Staging System.
Barros-Gomes S; Williams B; Nhola LF; Grogan M; Maalouf JF; Dispenzieri A; Pellikka PA; Villarraga HR
JACC Cardiovasc Imaging; 2017 Apr; 10(4):398-407. PubMed ID: 27639764
[TBL] [Abstract][Full Text] [Related]
10. Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis.
Palladini G; Campana C; Klersy C; Balduini A; Vadacca G; Perfetti V; Perlini S; Obici L; Ascari E; d'Eril GM; Moratti R; Merlini G
Circulation; 2003 May; 107(19):2440-5. PubMed ID: 12719281
[TBL] [Abstract][Full Text] [Related]
11. Comparison of different types of cardiac amyloidosis by cardiac magnetic resonance imaging.
Kristen AV; aus dem Siepen F; Scherer K; Kammerer R; Andre F; Buss SJ; Bauer R; Lehrke S; Voss A; Giannitsis E; Katus HA; Steen H
Amyloid; 2015; 22(2):132-41. PubMed ID: 26053103
[TBL] [Abstract][Full Text] [Related]
12. When and how do patients with cardiac amyloidosis die?
Escher F; Senoner M; Doerler J; Zaruba MM; Messner M; Mussner-Seeber C; Ebert M; Ensinger C; Mair A; Kroiss A; Ulmer H; Schneiderbauer-Porod S; Ebner C; Poelzl G
Clin Res Cardiol; 2020 Jan; 109(1):78-88. PubMed ID: 31134330
[TBL] [Abstract][Full Text] [Related]
13. A simple staging system using biomarkers for wild-type transthyretin amyloid cardiomyopathy in Japan.
Nakashima N; Takashio S; Morioka M; Nishi M; Yamada T; Hirakawa K; Ishii M; Tabata N; Yamanaga K; Fujisue K; Sueta D; Kanazawa H; Hoshiyama T; Hanatani S; Araki S; Usuku H; Yamamoto E; Ueda M; Matsushita K; Tsujita K
ESC Heart Fail; 2022 Jun; 9(3):1731-1739. PubMed ID: 35191205
[TBL] [Abstract][Full Text] [Related]
14. Circulating matrix metalloproteinases and tissue inhibitors of metalloproteinases in cardiac amyloidosis.
Tanaka K; Essick EE; Doros G; Tanriverdi K; Connors LH; Seldin DC; Sam F
J Am Heart Assoc; 2013 Mar; 2(2):e005868. PubMed ID: 23537813
[TBL] [Abstract][Full Text] [Related]
15. Natural History of Wild-Type Transthyretin Cardiac Amyloidosis and Risk Stratification Using a Novel Staging System.
Grogan M; Scott CG; Kyle RA; Zeldenrust SR; Gertz MA; Lin G; Klarich KW; Miller WL; Maleszewski JJ; Dispenzieri A
J Am Coll Cardiol; 2016 Sep; 68(10):1014-20. PubMed ID: 27585505
[TBL] [Abstract][Full Text] [Related]
16. Diagnostic pathways to wild-type transthyretin amyloid cardiomyopathy: a multicentre network study.
Tini G; Milani P; Zampieri M; Caponetti AG; Fabris F; Foli A; Argirò A; Mazzoni C; Gagliardi C; Longhi S; Saturi G; Vergaro G; Aimo A; Russo D; Varrà GG; Serenelli M; Fabbri G; De Michieli L; Palmiero G; Ciliberti G; Carigi S; Sessarego E; Mandoli GE; Ricci Lucchi G; Rella V; Monti E; Gardini E; Bartolotti M; Crotti L; Merli E; Mussinelli R; Vianello PF; Cameli M; Marzo F; Guerra F; Limongelli G; Cipriani A; Perlini S; Obici L; Perfetto F; Autore C; Porto I; Rapezzi C; Sinagra G; Merlo M; Musumeci B; Emdin M; Biagini E; Cappelli F; Palladini G; Canepa M
Eur J Heart Fail; 2023 Jun; 25(6):845-853. PubMed ID: 36907828
[TBL] [Abstract][Full Text] [Related]
17. [The importance of cardiac bio-marker assay for the stratification and monitoring of AL amyloidosis patients - single center experience].
Pika T; Lochman P; Vymětal J; Metelka R; Flodr P; Minařík J; Látalová P; Zapletalová J; Bačovský J; Sčudla V
Vnitr Lek; 2013 Sep; 59(9):776-81. PubMed ID: 24073949
[TBL] [Abstract][Full Text] [Related]
18. Cardiovascular magnetic resonance and prognosis in cardiac amyloidosis.
Maceira AM; Prasad SK; Hawkins PN; Roughton M; Pennell DJ
J Cardiovasc Magn Reson; 2008 Nov; 10(1):54. PubMed ID: 19032744
[TBL] [Abstract][Full Text] [Related]
19. Best use of cardiac biomarkers in patients with AL amyloidosis and renal failure.
Palladini G; Foli A; Milani P; Russo P; Albertini R; Lavatelli F; Obici L; Perlini S; Moratti R; Merlini G
Am J Hematol; 2012 May; 87(5):465-71. PubMed ID: 22389105
[TBL] [Abstract][Full Text] [Related]
20. Different NT-proBNP circulating levels for different types of cardiac amyloidosis.
Perfetto F; Bergesio F; Grifoni E; Fabbri A; Ciuti G; Frusconi S; Angelotti P; Spini V; Cappelli F
J Cardiovasc Med (Hagerstown); 2016 Nov; 17(11):810-7. PubMed ID: 26765991
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]